Estimate Parkinson risk after pesticides
- Trial ID
- NCT06420310
- Official Title
- Prevalence of Preclinical and Prodromal Parkinson´s Disease in Subjects Exposed to Pesticides
- Goal
- Estimate Parkinson risk after pesticides
- Status
- RECRUITING
- Sponsor
- Hospital Universitario de Burgos
- Study Type
- OBSERVATIONAL
- Enrollment
- 260 participants
- Conditions
- Pesticide-Induced Parkinsonism
- Interventions
- exposure to pesticides
Summary For Families
The goal is to find out whether people who work with pesticides are more likely to have preclinical or prodromal signs of Parkinson's, so we can better understand pesticide-related Parkinsonism risk. The team will compare farmers with occupational pesticide exposure to people with no work exposure, screening both groups for early Parkinson's signs and markers to estimate how common these early stages are after pesticide exposure. About 260 adults aged 45 to 55 are being enrolled, with cases being farmers exposed to pesticides, controls having no work exposure, and people excluded if they do not consent or have other significant neurological conditions.
Locations
- Hospital Universitario de Burgos, Burgos, Spain
Frequently Asked Questions
- What is this trial testing?
- This trial is studying exposure to pesticides. The goal is to find out whether people who work with pesticides are more likely to have preclinical or prodromal signs of Parkinson's, so we can better understand pesticide-related Parkinsonism risk. The team will compare farmers with occupational pesticide exposure to people with no work exposure, screening both groups for early Parkinson's signs and markers to estimate how common these early stages are after pesticide exposure. About 260 adults aged 45 to 55 are being enrolled, with cases being farmers exposed to pesticides, controls having no work exposure, and people excluded if they do not consent or have other significant neurological conditions.
- Who can participate?
- Participants must be between 45 Years and 55 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years and 6 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.